SciELO - Scientific Electronic Library Online

 
vol.21 suppl.2Incidencia y factores de riesgo para enterocolitis necrosante en una cohorte de prematuros menores de 1500 gramosAnálisis de asociación de variantes en genes del sistema serotoninérgico con conducta suicida en pacientes con trastorno depresivo mayor: informe parcial sobre las características clínicas y sociodemográficas índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Iatreia

versión impresa ISSN 0121-0793

Iatreia v.21  supl.2 Medellín dic. 2008

 

Pregabalin as a perioperative strategy for pain management in patients undergoing cosmetic surgery. A randomized, double–blind, and placebo–controlled study

 

Luis Enrique Chaparro Gómez1; Paola Valdés Cuartas2; Mauricio Mira Correa2; Fernando Montoya Maya3; Lorena Duque4

1. MD, Professor of Anesthesia, Universidad de Antioquia, Medellín, Colombia. Clinical Fellow. Comprehensive Pain Program. Toronto Western Hospital. Toronto, Ontario

2.MD, Resident of Anesthesia, School of Medicine, University of Antioquia, Medellín, Colombia.

3. MD, Epidemiologist, School of Medicine, University of Antioquia, Medellín, Colombia.

4. RN, Epidemiologist, School of Nursing, University of Antioquia, Medellín, Colombia.

 


 

BACKGROUND: Preoperative Gabapentin has demonstrated to be as analgesic strategy in the control of perioperative pain. Pregabalin –an analogue of Gabapentin– has only a few trials demonstrating its effectiveness on this clinical setting. We wanted to assess the effectiveness of pregabalin given not only as a single dose in the preoperative period, but also continuing its administration 75 mg bid up to the fourth day after surgery.

METHODS: Previous consent by the Ethical Committee of the University, we enrolled 110 patients undergoing ambulatory liposuction. They were randomized and blindedallocated to receive Pregabalin (75 mg bid) versus placebo, starting 12 hours before surgery up to the fourth day after surgery. We use the postoperative pain intensity by numerical rating scale, pain intensity by categorical pain scale and tramadol–ibuprofen request as primary outcomes.

RESULTS: We had 9 dropouts during the recruitment and follow up. 24 hours after surgery we had 18/51 (35.3%) versus 16/50 (32%) (p=0.7). We also found no difference in opioid request at the same time point, being 6.3 mg morphine equivalents in the pregabalin versus 6.7 mg in the Placebo Group. Subsequent evaluations at 48, 72 and 96 hours demonstrated no difference between groups for analgesic request and pain intensity.

CONCLUSION: Perioperative use of Pregabalin (75 mg bid) does not offer benefit as analgesic strategy in terms of pain intensity and opioid requirement in patients undergoing cosmetic liposuction.

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons